🔬 Breakthroughs in Obesity Treatment: Latest Updates on GLP-1 Therapies & Biotech Advancements
The obesity treatment landscape is evolving rapidly, with new clinical trials, biotech innovations, and market shifts shaping the future of weight management.
In this episode of Obesity Updates, we cover the most significant breakthroughs, including:
💊 Allurion’s GLP-1 + Balloon Therapy – A novel approach to improving weight loss outcomes and treatment adherence.
🧬 Northstrive Biosciences’ EL-22 – A probiotic-based obesity therapy targeting the myostatin pathway.
📈 Ascletis’ ASC30 Oral GLP-1 Drug – Positive Phase Ib results show promising weight loss effects.
📉 Long-Acting GLP-1 Injections – How monthly and quarterly formulations are reshaping the obesity drug market.
🏭 Eli Lilly’s $550M Weight-Loss Pill Stockpile – Preparing for a major market entry with orforglipron. 🇰🇷 SK Pharmteco’s $1.5B Manufacturing Deal – South Korea emerges as a key player in obesity drug production.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates on obesity treatments and biotech breakthroughs.
#ObesityTreatment #GLP1 #WeightLossDrugs #Biotech #PharmaNews #ClinicalTrials #HealthcareInnovation